Question 1

What is Amyotrophic Lateral Sclerosis (ALS)?

Accepted Answer

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, specifically the motor neurons that control voluntary muscle movement.

Question 2

How is Amyotrophic Lateral Sclerosis (ALS) epidemiology segmented in 7MM?

Accepted Answer

The Amyotrophic Lateral Sclerosis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the Total Prevalent Population of ALS, Diagnosed ALS Prevalence of ALS, Type-specific Distribution of ALS, Gender-specific Distribution of ALS, Mutation-specific Distribution of ALS, Distribution Based on Site of Onset of ALS, and Age-specific Distribution of ALS in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

Question 3

Who are the leading companies in the Amyotrophic Lateral Sclerosis (ALS) market?

Accepted Answer

Major pharma Amyotrophic Lateral Sclerosis companies working in the ALS market are AB SCIENCE, ALECTOR, GSK, BRAINSTORM CELL THERAPEUTICS, IONIS PHARMACEUTICALS, MEDICINOVA, DENALI THERAPEUTICS, ABBVIE, CALICO LIFE SCIENCES, CLENE NANOMEDICINE BIOSCIENCES, SEELOS THERAPEUTICS, PRILENIA THERAPEUTICS, RAPA THERAPEUTICS, NEUROSENSE THERAPEUTICS, HELIXMITH, TRANSPOSON THERAPEUTICS, REVALESIO CORPORATION, ANNEXON BIOSCIENCES, CORCEPT THERAPEUTICS, AL-S PHARMA, SANOFI, DENALI THERAPEUTICS, ORPHAI THERAPEUTICS, and others.

Question 4

What is the total Amyotrophic Lateral Sclerosis (ALS) market size in the United States in 7MM?

Accepted Answer

The total Amyotrophic Lateral Sclerosis Market Size in the US was estimated to be ~USD 920 million in 2023, which is expected to grow during the forecast period (2024–2034).